The big boys' blood money

An American company is selling the right to use stem cells - vital components in the fight against blood disorders. What's wrong with that? Plenty, say scientists who plan to block the enterprise. By Charles Arthur

Should we be able to patent life? It's a question that, despite the growing number of patents granted on things such as genetically engineered vegetables and gene discoveries, has bubbled away within the world of science. Some say yes, definitely; others say no just as definitely. Later this summer, that argument is likely to boil over and become a lot more visible. Doctors and scientists across Europe are uniting to challenge a patent awarded to an American company, Biocyte, because they say it commercialises human life and could prevent lives being saved.

The row is over a patent granted by the European Patent Office to Biocyte, based in Pennsylvania. According to the patent, Biocyte has the rights to the use of any "stem cells" from umbilical blood. Anyone who wanted to use stem cells for a medical procedure - and that includes the process of collecting and storing them - would have to apply for a licence and possibly pay a royalty to the company, under the terms of the patent.

It might seem surprising in the first place that a commercial entity could patent something so ubiquitous as the blood cells found in the umbilical cord between mother and child. But don't forget that other companies, and research organisations, have patented human genes: for example, the breast cancer genes BRCA1 and BRCA2 are in effect "owned" by their discoverers on both sides of the Atlantic.

What has infuriated doctors about the Biocyte patent is that, unlike possible diagnoses and cures for BRCA-induced cancers, the use of stem cells is very immediate. In effect, they are "mother cells" of blood - when introduced into diseased parts of the body, they can repopulate it with new, healthy blood cells. The method has already been used in more than 500 cases as an alternative to replacing diseased bone marrow. Stem cells only exist in the foetus; after birth, it is the bone marrow which produces new blood cells.

Biocyte says that it should be allowed to patent the cells because it did much of the original work which discovered their function and ability to effect a cure. Chris Moller, the company president, says: "We spent more than $8 million [pounds 5 million] on this. We want to be appropriately rewarded. Who else thought of doing this and creating a commercial enterprise around it?"

Who indeed? The fact is that in Europe, the second sentence rarely enters the equation. Dr Marcela Contreras, executive director of the Blood Transfusion Service (BTS) in London, says: "Biocyte say they wanted the patent because speculators in the US have been freezing babies' stem cells for future use. But nobody's doing that in Europe, so why patent it over here?

"The patent is too broad. Life should not be patented. I'm all for patenting drugs, but not things that aren't real inventions. I don't see how you can patent life."

That's why Eurocord, a consortium of national blood transfusion services from the UK, France, Germany, Spain and the Netherlands, and the European Bone Marrow Association, are challenging the award of the patent to Biocyte. Their appeal should be heard within three months.

Part of the BTS's anger is derived from the fact that it has been expanding its collection of "cord blood", gathered with the consent of mothers (otherwise, its collection would legally count as assault). "We have 680 units, but by the end of the year we should have 2,000, and in three years' time 10,000 units," Dr Contreras says. The most important part of that growth in stocks is among people in ethnic minorities, who have been under-represented both in blood stocks and in potential bone marrow donors.

"Cord blood is useful for treating both inherited haemolytic disorders such as thalassaemia, and malignancies," says Dr Contreras. "It can also be used for children and young adults who can't find a matching bone-marrow donor."

Stem cells also have a significant advantage for blood disease treatment over bone marrow. Immunologists have identified that we have six categories of HLA (human leukocyte antibody) in our cells. A bone marrow donation must match in all six categories, which is why identical siblings are the ideal donor, as they come from the same embryo. But stem cells need only match in five of the six categories, greatly extending the chances of a match. Otherwise, your chances of finding a matching donor are fewer than one in 10,000.

Biocyte has told doctors that it will not levy a charge for non-commercial use of stem cells, though nobody is quite sure how that would apply in a health service where money ostensibly changes hands, even if only in the internal market. "Biocyte were challenged to confirm that by the New York Blood Centre, which is a non-profit organisation," says Dr Contreras. "The reply was, 'We won't charge you for a year.' We said that we would like this no-charge promise confirmed in writing, to tell us that we won't be charged for collecting and storing cord blood. We haven't heard anything."

The Biocyte patent cuts to the heart of the row over patenting of biological entities, though the issue itself is not new. Scientists are increasingly worried that the idea of researchers sharing useful information is being eroded by the fear that any information they let slip will somehow prove vital to a rival's efforts, and that consequently they will miss out not only on the glory, but also the riches. One eminent British scientist suggested recently that this has happened over the BRCA searches. Similarly, researchers investigating cystic fibrosis - the most common inherited genetic disorder - have received bills from the University of Michigan and the Toronto hospital which had patented the gene after they discovered it.

The idea of patents as a lawful means of protecting new inventions and techniques is far more easy to understand in the case even of the oncomouse, developed at Harvard University with the intention that it would develop cancer (because of a genetic alteration). The ethical position was always doubtful, but there was no gainsaying the fact that the oncomouse species had never existed before. It was not a discovery; it was an invention. Scientists in Britain are increasingly worried about the breadth of the European patent law, especially the new drafts that have been emerging from Brussels and the European Parliament. The Department of Trade and Industry said, before the election, that it was doing its best to defend Britain's interests. It will be interesting to see what happens now.

There is one image that will surely turn the public against the patenting law - that of a dying child whose parents and doctors are having to pay money to an American company because of a bizarre European law n

PROMOTED VIDEO
News
ebooksAn evocation of the conflict through the eyes of those who lived through it
Life and Style
techApp to start sending headlines, TV clips and ads to your phone
Arts and Entertainment
Taylor Swift crawls through the legs of twerking dancers in her 'Shake It Off' music video
musicEarl Sweatshirt thinks so
Life and Style
tech
Arts and Entertainment
Daniel Radcliffe and Zoe Kazan in What If
filmReview: Actor swaps Harry Potter for Cary Grant in What If
News
Our resilience to stress is to a large extent determined by our genes
science
Independent
Travel Shop
the manor
Up to 70% off luxury travel
on city breaks Find out more
santorini
Up to 70% off luxury travel
on chic beach resorts Find out more
sardina foodie
Up to 70% off luxury travel
on country retreats Find out more
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Asset Finance Solicitor

Highly Competitive Salary: Austen Lloyd: CITY - ASSET FINANCE - An outstanding...

HR Analyst - Banking - Bristol - £350-£400

£350 - £400 per day: Orgtel: HR Analyst - Banking - Bristol - £350 - £400 per ...

Assistant Marketing & PR Manager

£16 - £17 per hour: Ashdown Group: Marketing & PR Assistant - Kentish Town are...

Project Manager (App development, SAP, interfacing)

£50000 - £60000 Per Annum + excellent company benefits: Clearwater People Solu...

Day In a Page

Ferguson: In the heartlands of America, a descent into madness

A descent into madness in America's heartlands

David Usborne arrived in Ferguson, Missouri to be greeted by a scene more redolent of Gaza and Afghanistan
BBC’s filming of raid at Sir Cliff’s home ‘may be result of corruption’

BBC faces corruption allegation over its Sir Cliff police raid coverage

Reporter’s relationship with police under scrutiny as DG is summoned by MPs to explain extensive live broadcast of swoop on singer’s home
Lauded therapist Harley Mille still in limbo as battle to stay in Britain drags on

Lauded therapist still in limbo as battle to stay in Britain drags on

Australian Harley Miller is as frustrated by court delays as she is with the idiosyncrasies of immigration law
Lewis Fry Richardson's weather forecasts changed the world. But could his predictions of war do the same?

Lewis Fry Richardson's weather forecasts changed the world...

But could his predictions of war do the same?
Kate Bush asks fans not to take photos at her London gigs: 'I want to have contact with the audience, not iPhones'

'I want to have contact with the audience, not iPhones'

Kate Bush asks fans not to take photos at her London gigs
Under-35s have rated gardening in their top five favourite leisure activities, but why?

Young at hort

Under-35s have rated gardening in their top five favourite leisure activities. But why are so many people are swapping sweaty clubs for leafy shrubs?
Tim Vine, winner of the Funniest Joke of the Fringe award: 'making a quip as funny as possible is an art'

Beyond a joke

Tim Vine, winner of the Funniest Joke of the Fringe award, has nigh-on 200 in his act. So how are they conceived?
The late Peter O'Toole shines in 'Katherine of Alexandria' despite illness

The late Peter O'Toole shines in 'Katherine of Alexandria' despite illness

Sadly though, the Lawrence of Arabia star is not around to lend his own critique
Wicken Fen in Cambridgeshire: The joy of camping in a wetland nature reserve and sleeping under the stars

A wild night out

Wicken Fen in Cambridgeshire offers a rare chance to camp in a wetland nature reserve
Comic Sans for Cancer exhibition: It’s the font that’s openly ridiculed for its jaunty style, but figures of fun have their fans

Comic Sans for Cancer exhibition

It’s the font that’s openly ridiculed for its jaunty style, but figures of fun have their fans
Besiktas vs Arsenal: Five things we learnt from the Champions League first-leg tie

Besiktas vs Arsenal

Five things we learnt from the Champions League first-leg tie
Rory McIlroy a smash hit on the US talk show circuit

Rory McIlroy a smash hit on the US talk show circuit

As the Northern Irishman prepares for the Barclays, he finds time to appear on TV in the States, where he’s now such a global superstar that he needs no introduction
Boy racer Max Verstappen stays relaxed over step up to Formula One

Boy racer Max Verstappen stays relaxed over step up to F1

The 16-year-old will become the sport’s youngest-ever driver when he makes his debut for Toro Rosso next season
Fear brings the enemies of Isis together at last

Fear brings the enemies of Isis together at last

But belated attempts to unite will be to no avail if the Sunni caliphate remains strong in Syria, says Patrick Cockburn
Charlie Gilmour: 'I wondered if I would end up killing myself in jail'

Charlie Gilmour: 'I wondered if I'd end up killing myself in jail'

Following last week's report on prison suicides, the former inmate asks how much progress we have made in the 50 years since the abolition of capital punishment